Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases
Visit us on the Web
NIAID Starts Clinical Trial of Possible Therapy for EGPA
A new NIAID-supported clinical trial is evaluating a possible therapy for people with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA, previously known as Churg-Strauss syndrome, is characterized by widespread inflammation in the walls of small blood vessels and can affect multiple organs, including the heart, lungs, skin, GI tract, kidneys and nervous system. This Phase III study is the first ever double-blind, placebo-controlled study to be conducted in patients with EGPA.
Read more about the study, eligibility requirements, and study site locations (ClinicalTrials.gov ID NCT2020889) http://